IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of:

Akira NAKAMURA et al.

Art Unit: 1632

Appl. No: 10/009,950

Examiner: Valarie E. Bertoglio

Confirmation No: 7278

Atty. Docket No: 31671-176197

Filed: December 14, 2001

Customer No:

For: GOODPASTURE'S SYNDROME

MODEL MOUSE

Information Disclosure Statement Under 37 C.F.R. § 1.97(c)

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(c)(2).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.

The Information Disclosure Statement is being filed after the mailing date of a first Office action on the merits, but before receipt of an action that closes prosecution in the application. Accordingly, pursuant to 37 C.F.R. §1.97(c)(2), a fee of \$180.00 is attached.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

If no check is attached, please charge any necessary fee or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Date: 8/18/04

Ann S. Hobbs, Ph.D. Registration No. 36,830

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

#571395v1

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

THADE Stitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Complete if Known				
Application Number	10/009,950			
Filing Date	12/04/2001			
First Named Inventor	Akira NAKAMURA			
Group Art Unit	1632			
Examiner Name	V. BERTOGLIO			
Attorney Docket Number	31671-176197			

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	A1	W. Kline BOLTON et al., "Goodpasture's Epitope in Development of Experimental Autoimmune Glomerulonephritis in Rats", Kidney International, Vol. 49, (1996), pp. 327-334.				
	A2	Mauro Abbate et al., "Experimental Goodpasture's Syndrome in Wistar- Kyoto Rats Immunized with a3 Chain of Type IV Collagen", Kidney International, Vol. 54 (1998), pp. 1550-1561.				
	A3	Raghu KALLURI, "Goodpasture Syndrome", Kidney International, Vol. 55 (1999), pp 1120-1122.				
		· ·				
		, .				

		· · · · · · · · · · · · · · · · · · ·
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



